TAA05
/ PersonGen Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 06, 2022
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Wuhan Union Hospital, China
CAR T-Cell Therapy • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
June 27, 2022
TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3 • IL6
1 to 2
Of
2
Go to page
1